# Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

> **NCT02743923** · PHASE3 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 203 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Pemetrexed
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT02743923
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2021-09-19
- **Final completion:** 2024-04
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2021-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743923, "Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02743923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*